Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
By B. Bielekova, M. Catálfamo, Susan A. Reichert-Scrivner, Amy N. Packer, M. Cerná, T. Waldmann, H. McFarland, P. Henkart, Roland Martin. Proceedings of the National Academy of Sciences of the United States of America, 2006
625 citations recorded by the source corpus.
Subfields: Immunology
View Paper: https://www.semanticscholar.org/paper/a28fc983d621c72106e91f2c1de45f390caa7817
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- Multiple sclerosis: a complicated picture of autoimmunity (2007, background): “However, the additional regulatory cell type that has been noted in daclizumab-treated patients with multiple sclerosis belongs to the natural killer lineage and is characterized as 'CD56 bright”